Christopher D. Benjamin
17Patents
11h-index
14Co-inventors
69Inventor score
Filing activity: Dec 18, 1989 → Oct 21, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5272263A | DNA sequences encoding vascular cell adhesion molecules (VCAMS) | Emerging Cross-Sectional Technologies | 47 | Expired |
| US5925351A | Soluble lymphotoxin-.beta. receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease | Emerging Cross-Sectional Technologies | 39 | Expired |
| US6323027A | Common gamma chain monoclonal antibody blocking agents | Chemistry; Metallurgy | 28 | Expired |
| US6312691A | Lymphotoxin-.alpha./.beta. complexes and anti-lympotoxin-.beta. receptor antibodies as anti-tumor agents | Emerging Cross-Sectional Technologies | 26 | Expired |
| US6403087B1 | Soluble lymphotoxin-&bgr; receptors as therapeutic agents for the treatment of immunological disease | Emerging Cross-Sectional Technologies | 25 | Expired |
| US7001598B2 | Anti-lymphotoxin-beta receptor antibodies as anti-tumor agents | Emerging Cross-Sectional Technologies | 24 | Expired |
| US6669941B1 | Soluble lymphotoxin-&bgr; receptor as a therapeutic agent for treating TH-1 cell-associated autoimmune disease | Emerging Cross-Sectional Technologies | 23 | Expired |
| US5367056A | Endothelial cell-leukocyte adhesion molecules (ELAMs) and molecules involved in leukocyte adhesion (MILAs) | Emerging Cross-Sectional Technologies | 22 | Expired |
| US6252043A | Vascular cell adhesion molecule (VCAM) polypeptides | Emerging Cross-Sectional Technologies | 21 | Expired |
| US6770745B2 | Common gamma chain blocking agents | Chemistry; Metallurgy | 19 | Expired |
| US6307025A | VCAM fusion proteins and DNA coding therefor | Emerging Cross-Sectional Technologies | 16 | Expired |
| US7459537B2 | Anti-lymphotoxin-β receptor antibodies as anti-tumor agents | Emerging Cross-Sectional Technologies | 6 | Expired |
| US7427403B2 | Methods for inhibiting lymphotoxin β receptor signalling | Emerging Cross-Sectional Technologies | 5 | Expired |
| US10989681B2 | Grid coatings for capture of proteins and other compounds | Physics | 1 | Active |
| US7951371B2 | Soluble lymphotoxin-β receptor fusion protein and methods for inhibiting lymphotoxin β-receptor signaling | Emerging Cross-Sectional Technologies | 1 | Active |
| US8455445B2 | Methods for inhibiting lymphotoxin-β receptor signaling in TH1 cell-associated disorders | Emerging Cross-Sectional Technologies | 0 | Active |
| US11965851B2 | Grid coatings for capture of proteins and other compounds | Physics | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.